Hiroaki Nonaka

Cancer Incidence in Atomic Bomb Survivors. Part III: Leukemia, Lymphoma and Multiple Myeloma, 1950-1987

Dale L. Preston, Shizuyo Kusumi, Masao Tomonaga et al. · Radiation Research · 1994 · 799 citations

Mixed-phenotype Acute Leukemia, Radiation Exposure, Pathology +17

Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy

Dongdong Wang, Yasushi Saga, Hiroaki Mizukami et al. · International Journal of Oncology · 2011 · 71 citations · Full text

Immunosuppressive Enzyme, Cancer-associated Virus, Oncogenic Agent +15

Dysmegakaryocytopoiesis in acute leukaemias: its predominance in myelomonocytic (M4) leukaemia and implication for poor response to chemotherapy

Itsuro Jinnai, Masao Tomonaga, Kazutaka Kuriyama et al. · British Journal of Haematology · 1987 · 63 citations

Mixed-phenotype Acute Leukemia, Immunology, Pathology +17

Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion.

Hiroaki Nonaka, Yasushi Saga, Hiroyuki Fujiwara et al. · PubMed · 2011 · 50 citations

Chemoprevention Strategy, Oncogenic Agent, Medicine +14

Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation

Naoto Sato, Yasushi Saga, Hiroaki Mizukami et al. · Oncology Reports · 2012 · 44 citations · Full text

Chemoprevention Strategy, Immunology, Nk Cells +20